Structure Activity Relationship forms the basis of Rational Drug Design in the circles of pharmaceutical and medicinal chemistry. Appropriate knowledge of functional outcomes of structural modifications is crucial in conferring desired pharmacological properties to a chemical compound. Amiodarone is a classical antiarrythmic agent with a long list of adverse effects. This article attempts to review the structure activity relationship of some of the homologues of amiodarone in order to determine the most clinically desirable molecule.
References
[1]
Freemantle, M. (2005) Top Pharmaceuticals That Changed the World. Chemical and Engineering News, 83, 3.
[2]
Heijman, J. and Dobrev, D. (2013) Pleiotropic Actions of Amiodarone: Still Puzzling after Half a Century. Naunyn- Schmiedeberg’s Archives of Pharmacology, 386, 571-574. http://dx.doi.org/10.1007/s00210-013-0865-0
[3]
Rosenbaum, M.B., Chiale, P.A., Halpern, M.S., Nau, G.J., Przybylski, J., Levi, R.J., Lazzari, J.O. and Elizari, M.V. (1976) Clinical Efficacy of Amiodarone as an Antiarrhythmic Agent. American Journal of Cardiology, 38, 934-944.
http://dx.doi.org/10.1016/0002-9149(76)90807-9
[4]
Kudenchuk, P.J., Cobb, L.A. and Copass, M.K. (1999) Amiodarone for Resuscitation after Out-of-Hospital Cardiac Arrest Due to Ventricular Fibrillation. The New England Journal of Medicine, 341, 871-878.
[5]
Guarnieri, T., Nolan, S., Gottlieb, S.O., Dudek, A. and Lowry, D.R. (1999) Intravenous Amiodarone for the Prevention of Atrial Fibrillation after Open Heart Surgery: The Amiodarone Reduction in Coronary Heart (ARCH) Trial. Journal of the American College of Cardiology, 34, 343-347. http://dx.doi.org/10.1016/S0735-1097(99)00212-0
[6]
Naccarelli, G.V., Rinkenberger, R.L., Dougherty, A.H. and Fitzgerald, D.M. (1989) Adverse Effects of Amiodarone. Medical Toxicology and Adverse Drug Experience, 4, 246-253. http://dx.doi.org/10.1007/BF03259911
[7]
Kodama, I., Kamyia, K. and Toyoma, J. (1999) Amiodarone: Ionic and Cellular Mechanism of Action of the Most Promising Class III Agent. American Journal of Cardiology, 84, 20-28.
http://dx.doi.org/10.1016/S0002-9149(99)00698-0
[8]
Quaglino, D., Ha, H.R., Duner, E., Bruttomesso, D., Bigher, L., Follath, F., Realdi, G., Pettenazzo, A. and Baritussio, A. (2004) Effects of Metabolites and Analogues of Amiodarone on Alveolar Macrophages: Structure Activity Relationship. American Journal of Physiology—Lung Cellular and Molecular Physiology, 287, L438-L447.
http://dx.doi.org/10.1152/ajplung.00434.2003
[9]
Kathofer, S., Thomas, D. and Karle, C.A. (2005) The Novel Antiarrhythmic Drug Dronedarone: Comparison with Amiodarone. Cardiovascular Drug Reviews, 23, 217-230. http://dx.doi.org/10.1111/j.1527-3466.2005.tb00167.x
[10]
Iram, F., Ali, S., Ahmad, A., Khan, S.A. and Husain, A. (2016) A Review on Dronedarone: Pharmacological, Pharmacodynamic and Pharmacokinetic Profile. Journal of Acute Disease, 5, 102-108.
http://dx.doi.org/10.1016/j.joad.2015.10.002
[11]
Zimetbaum, P.J. (2009) Dronedarone for Atrial Fibrillation—An Odyssey. The New England Journal of Medicine, 360, 1811-1813. http://dx.doi.org/10.1056/NEJMp0902248
[12]
Kober, L., Torp-Pedersen, C., McMurray, J., Gotzsche, O., Lévy, S., Crijns, H., Amlie, J., Carlsen, J. and Dronedarone Study Group (2008) Increased Mortality after Dronedarone Therapy for Severe Heart Failure. The New England Journal of Medicine, 358, 2678-2687. http://dx.doi.org/10.1056/NEJMoa0800456
[13]
FDA Drug Safety Communication (2011) Severe Liver Injury Associated with the Use of Dronedarone (Marketed as Multaq). http://www.fda.gov/Drugs/DrugSafety/ucm240011.htm
[14]
Morey, T.E., Seubert, C.N., Raatikainen, M.J.P., Martynyuk, A.E., Druzgala, P., Milner, P., Gonzalez, M.D. and Dennis, D.M. (2001) Structure-Activity Relationships and Electrophysiological Effects of Short Acting Amiodarone Homologues in Guinea Pig Isolated Heart. Journal of Pharmacology and Experimental Therapeutics, 297, 260-266.
[15]
Hohnloser, S.H., Halperin, J.L., Camm, A.J., Gao, P., Radzik, D. and Connolly, S.J. (2014) Interaction between Digoxin and Dronedarone in the PALLAS Trial. Circulation: Arrhythmia and Electrophysiology, 7, 1019-1025.
http://dx.doi.org/10.1161/CIRCEP.114.002046
[16]
Huemer, M., Sarganas, G., Bronder, E., Klimpel, A., Garbe, E. and Haverkamp, W. (2015) Torsade de Pointes Tachycardia in a Patient Ondronedarone Therapy. Pharmacotherapy, 35, e61-e65. http://dx.doi.org/10.1002/phar.1573
[17]
Piccini, J.P., Hasselblad, V., Peterson, E.D., Washam, J.B., Califf, R.M. and Kong, D.F. (2009) Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients with Atrial Fibrillation. Journal of the American College of Cardiology, 54, 1089-1095. http://dx.doi.org/10.1016/j.jacc.2009.04.085
[18]
U.S. Food and Drug Administration (2011) FDA Drug Safety Communication: Severe Liver Injury Associated with the Use of Dronedarone (Marketed as Multaq). U.S. Food and Drug Administration, Maryland.
http://www.fda.gov/drugs/drugsafety/ucm240011.htm
[19]
Wood, S. (2011) Deaths Doubled with Dronedarone in PALLAS: FDA and EMA Updates. Medscape, New York.
http://www.theheart.org/article/1255799.do
[20]
ClinicalTrials.gov. (2014) Optimal Timing of Dronedarone Initiation after Conversion in Patients with Persistent Atrial Fibrillation (ARTEMIS Load). http://clinicaltrials.gov/ct2/show/NCT01140581
[21]
Freemantle, N., Lafuente-Lafuente, C., Mitchell, S., Eckert, L. and Reynolds, M. (2011) Mixed Treatment Comparison of Dronedarone, Amiodarone, Sotalol, Flecainide, and Propafenone, for the Management of Atrial Fibrillation. Europace, 13, 329-345. http://dx.doi.org/10.1093/europace/euq450
[22]
Klieber, S., Arabeyre-Fabre, C., Moliner, P., Marti, E., Mandray, M., Ngo, R., et al. (2014) Identification of Metabolic Pathways and Enzyme Systems Involved in the in Vitro Human Hepatic Metabolism of Dronedarone, a Potent New Oral Antiarrhythmic Drug. Pharmacology Research & Perspectives, 2, e00044. http://dx.doi.org/10.1002/prp2.44
[23]
Rosa, G.M., Ferrero, S. and Brunelli, C. (2014) Pharmacokinetic and Pharmacodynamics Profile of Dronedarone, a New Antiarrhythmic Agent for the Treatment of Atrial Fibrillation. Expert Opinion on Drug Metabolism & Toxicology, 10, 1751-1764. http://dx.doi.org/10.1517/17425255.2014.974551
[24]
Chopra, S., Badyal, D.K. and Baby, C.P. (2013) Dronedarone: A New Therapeutic Agent for Atrial Fibrillation. JK Science, 15, 3-6.
[25]
Damy, T., Pousset, F., Caplain, H., Hulot, J.S. and Lechat, P. (2004) Pharmacokinetics and Pharmacodynamics Interactions between Metoprolol and Dronedarone in Extensive and Poor CYP2D6 Metabolizers Healthy Subjects. Fundamental & Clinical Pharmacology, 18, 113-123. http://dx.doi.org/10.1046/j.1472-8206.2003.00216.x
[26]
U.S. Food and Drug Administration (2010) Cordarone (Amiodarone HCL) Tablets: Package Insert. U.S. Food and Drug Administration, Maryland. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018972s042lbl.pdf
